CONTENTS Chapter 1 General introduction: management of patients with atrial fibrillation 9 Chapter 2 Atrial fibrillation: a systemic cardiovascular disease in need for integrated cardiovascular risk management 19 Chapter 3 Sex- and age specific association of new-onset atrial fibrillation with in-hospital mortality in hospitalised COVID-19 patients 29 Chapter 4 Stroke rate variation and anticoagulation benefit in atrial fibrillation 57 Chapter 5 Atrial fibrillation: trends in prevalence and antithrombotic prescriptions in the community 63 Chapter 6 Safety of switching from a vitamin K antagonist to a non- vitamin K antagonist oral anticoagulant in frail older patients with atrial fibrillation: rationale and design of the FRAIL-AF randomised controlled trial 85 Chapter 7 Safety of switching from a vitamin K antagonist to a nonvitamin K antagonist oral anticoagulant in frail older patients with atrial fibrillation: results of the FRAIL-AF randomised controlled trial 105 Chapter 8 Clinical consequences of off-label reduced dosing of nonvitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis 133 Chapter 9 General discussion: from management of patients with atrial fibrillation to the ‘inverse research law’ 177 Appendices Summary 193 Samenvatting 203 Dankwoord 213 About the author 221 Publications and conference presentations 225
RkJQdWJsaXNoZXIy MTk4NDMw